Secures Highly Dilutive $50M Equity Line of Credit with Deep Discount and Issues Pre-Funded Warrants

summarizeSummary

Tivic Health Systems secured a $50 million equity line of credit with Tumim Stone Capital, allowing the company to sell shares at a deep discount to market prices, and issued pre-funded warrants as a commitment fee.

check_boxKey Events

• Establishes $50 Million Equity Line of Credit

  The company entered into a Common Stock Purchase Agreement with Tumim Stone Capital, LLC, granting Tivic Health the right, but not the obligation, to sell up to $50,000,000 of newly issued common stock.

• Shares to be Sold at Deep Discount

  Shares purchased under the agreement will be priced at a discount, specifically 97% of the volume-weighted average price (VWAP) for a one-day valuation period or 95% of the lowest daily VWAP for a three-day valuation period.

• Issues Pre-Funded Warrants as Commitment Fee

  As consideration for the commitment, Tivic Health issued pre-funded warrants to purchase 437,012 shares of common stock to Tumim Stone Capital at a nominal exercise price of $0.0001 per share.

• Initial Dilution Limited by Exchange Cap

  The company is initially limited to issuing shares not exceeding 19.99% of its outstanding common stock (506,848 shares) without shareholder approval, unless the average sale price equals or exceeds $1.02 per share. Given the current stock price of $0.91, this cap is likely in effect.

auto_awesomeAnalysis

Tivic Health Systems, a nano-cap company, has entered into a highly dilutive equity line of credit agreement for up to $50 million with Tumim Stone Capital, LLC. This financing, which follows a recent shareholder vote seeking approval for dilutive agreements, provides a critical capital infusion but at a significant cost to existing shareholders. The shares will be sold at a deep discount to the market price (95-97% of VWAP), and a substantial commitment fee was paid in the form of pre-funded warrants. Given the company's small market capitalization, the potential for $50 million in dilution is extreme, even with an initial 19.99% exchange cap. This type of financing is often a last resort for companies facing severe liquidity challenges, indicating significant financial distress and placing considerable downward pressure on the stock.